Gene- and cell-based therapeutics for type I diabetes mellitus.
Type 1 diabetes mellitus, an autoimmune disorder is an attractive candidate for gene and cell-based therapy. From the use of gene-engineered immune cells to induce hyporesponsiveness to autoantigens to islet and beta cell surrogate transplants expressing immunoregulatory genes to provide a local pocket of immune privilege, these strategies have demonstrated proof of concept to the point where translational studies can be initiated. Nonetheless, along with the proof of concept, a number of important issues have been raised by the choice of vector and expression system as well as the point of intervention; prophylactic or therapeutic. An assessment of the current state of the science and potential leads to the conclusion that some strategies are ready for safety trials while others require varying degrees of technical and conceptual refinement.
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
R
R
Bottino
P
P
Lemarchand
M
M
Trucco
N
N
Giannoukakis
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000637:transplantation; D015551:Autoimmunity; D016026:Bone Marrow Transplantation; D018925:Chemokines / Q000235:genetics / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000276:immunology; D051379:Mice; D023421:Models, Animal; D011384:Proinsulin / Q000235:genetics; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous
D018925:Chemokines; D011384:Proinsulin